Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Gimv NV    GIMB   BE0003699130

GIMV NV

(GIMB)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensus 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
01/13/2021 01/14/2021 01/15/2021 01/18/2021 01/19/2021 Date
49.55(c) 49.15(c) 49(c) 49.7(c) 50.1 Last
9 812 9 044 12 981 14 054 4 162 Volume
-0.70% -0.81% -0.31% +1.43% +0.80% Change
More quotes
Financials
Sales 2019 226 M 273 M 273 M
Net income 2019 112 M 136 M 136 M
Net cash position 2019 277 M 335 M 335 M
P/E ratio 2019 11,3x
Yield 2019 5,00%
Sales 2020 147 M 178 M 178 M
Net income 2020 -152 M -184 M -184 M
Net cash position 2020 115 M 139 M 139 M
P/E ratio 2020 -7,98x
Yield 2020 5,26%
Capitalization 1 295 M 1 563 M 1 569 M
EV / Sales 2019 4,41x
EV / Sales 2020 7,43x
Nbr of Employees 91
Free-Float 72,8%
More Financials
Company
Gimv NV is one of the leading venture capital companies in Belgium. At the end of March 2020, the portfolio had an estimated market value of EUR 1,017 million broken down by type of shares as follows: - shares in unlisted companies (71.4%); - shares in listed companies (4.7%); - other (23.9%). Portfolio breaks down geographically by value as follows: Belgium (30.1%), the Netherlands (24.3%), France (18.1%),... 
More about the company
All news about GIMV NV
2020Gimv to Sell Majority Stake in Climate for Life to Parcom
MT
2020GIMV : sells Itho Daalderop-Climate for Life - Dutch market leader in integrated..
PU
2020Belgium's Gimv Joins $40 Million Funding Round For Kinaset Therapeutics
MT
2020GIMV : is founding investor of Kinaset Therapeutics in a USD 40m Series A round ..
PU
2020Investment Portfolio Growth Pushes Gimv H1 Profit Up
MT
2020Gimv Joins $43.7 Million Funding Round For SynOx Therapeutics
MT
2020GIMV : invests in SynOx Therapeutics which raises EUR 37 million to develop emac..
PU
2020GIMV NV : Press Release
CO
2020GIMV NV : Half-year results
CO
2020GIMV NV : Half-year report
CO
2020GIMV : ImCheck Announces Investment by BB Pureos Bioventures to Close Series B F..
PU
2020GIMV : Coordinated articles of association
PU
2020OUTCOME OF THE OPTIONAL DIVIDEND FOR : 63.4% of the dividend rights on the finan..
PU
2020GIMV NV : Dividends
CO
2020GIMV : Grandeco shifts up a gear thanks to the strategic acquisition of Holden D..
PU
More news
News in other languages on GIMV NV
2020GIMV : le groupe investit dans les laboratoires Biolam
2020GIMV : rapprochement entre Melijoe et The Babyshop Group
2020RÉSULTAT DU DIVIDENDE OPTIONNEL POUR : 63,4% des droits au dividende pour l'exer..
2020RÉSULTAT DU DIVIDENDE OPTIONNEL POUR : 63,4% des droits au dividende pour l'exer..
2020GIMV : Grandeco se renforce grâce à l'acquisition stratégique de Holden Decor Li..
More news
Chart GIMV NV
Duration : Period :
Gimv NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GIMV NV
Short TermMid-TermLong Term
TrendsNeutralBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 52,00 €
Last Close Price 49,70 €
Spread / Highest target 10,7%
Spread / Average Target 4,63%
Spread / Lowest Target -1,41%
Managers and Directors
NameTitle
Koen Dejonckheere Chief Executive Officer & Director
Hilde Laga Chairman
Kristof Vande Capelle Chief Financial Officer
Bart van Hooland Independent Non-Executive Director
Marc Descheemaecker Director
Sector and Competitors
1st jan.Capitalization (M$)
GIMV NV-0.60%1 563
BLACKROCK, INC.0.86%111 007
UBS GROUP AG7.58%54 050
BANK OF NEW YORK MELLON CORPORATION (THE)7.38%40 381
T. ROWE PRICE GROUP INC.3.32%35 419
STATE STREET CORPORATION6.05%27 229